Retrospective Cross-Sectional Study of Hematological and Biochemical Profile in Covid-19 Positive Patients and Their Association with Outcome
Authors
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Coronavirus disease (COVID-19) infection, can cause common cold symptoms to Acute Respiratory Distress syndrome, acute cardiac injury and multi-organ failure. Use of circulating biomarkers as the prognostic indicator of COVID-19-positive patients, may help in identifying target patients at higher risk. This study evaluated these hematological and biochemical parameters to find their association with outcome. Materials and Methods: This hospital-based retrospective cross-sectional study included 200 confirmed Covid 19 positive patients admitted at tertiary care hospital. Various hematological and biochemical parameters were studied and comparisons were drawn between initial and final measures in survivors and non-survivors using student t test and chi square test. Data analysis was done by using SPSS (version 22) for windows. Results: The mean age of non-survivors (69.21 ±10.46 years) was significantly higher compared to survivors (52.76 ±7.55). Risk factors like hypertension with diabetes mellitus was significantly higher in the non-survivor (23%) group compared to survivor group (9%). Total leukocyte count, total bilirubin, Aspartate aminotransferase, Alanine aminotransferase, C-Reactive Protein, D-dimer, Lactate dehydrogenase, ferritin, and Interleukin-6 were found to be significantly lower in survivors compared to non-survivors. Conclusion: The study envisages that hematological and biochemical parameters can identify patients at higher risk especially in scenarios of overwhelming patient volumes.
##plugins.themes.bootstrap3.article.details##
Copyright (c) 2025 Prakash Relwani, Sandeep Tekade, Neelam Redkar, Omkar Paradkar, Abhilasha Srivastava, Arun Saruk, Diksha Samsukha, Alhad Mulkalwar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons License All articles published in Annals of Medicine and Medical Sciences are licensed under a Creative Commons Attribution 4.0 International License.
[1] Coronavirus disease 2019 (COVID-19) Situation Report - 23. http://www.worldome ters.info.
[2] COVID-19 INDIA and state wise status as on: https://www.mohfw.gov.in/.
[3] Maharashtra Covid-19 Dashboard. https://arogya.maharashtra.gov.in/HYPERLINK. [Updated 2021 April 25; cited 2022 Apr 25].
[4] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727-733.
[5] Tan WJ, Zhao X, Ma XJ, et al. A novel coronavirus genome identified in a cluster of pneumonia cases - Wuhan, China 2019-2020. China CDC Weekly 2020; 2:61-62.
[6] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses Nature Microbiology. The species severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. 2020.
[7] Mahase E. China coronavirus: WHO declares international emergency as death toll exceeds 200. BMJ 2020;368:m408.
[8] The national health commission. Diagnosis and treatment scheme for coronavirus disease 2019 (Trial Version 5), 2.8; 2020.
[9] Sze S, Pan D, Nevill CR, Gray LJ, Martin CA, Nazareth J, Minhas JS, Divall P, Khunti K, Abrams KR, Nellums LB, Pareek M. Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. E Clinical Medicine. 2020 Dec; 29:100630.
[10] Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020 Jul;26(7):1017-1032.
[11] Daneshgaran G, Dubin DP, Gould DJ. Cutaneous Manifestations of COVID-19: An Evidence-Based Review. Am J Clin Dermatol. 2020 Oct;21(5):627-639.
[12] Hanson KE, Caliendo AM, Arias CA, Englund JA, Lee MJ, Loeb M, et al. Infectious diseases society of America guidelines on the diagnosis of COVID-Clin Infect Dis. 2020: 23 (2): 124-129.
[13] Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID‐Journal of Medical Virology. 2020.
[14] Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 May;40(5):998-1004.
[15] Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. (2001) 69:89-95.
[16] Albalawi O, Alharbi Y, Bakouri M, Alqahtani A, Alanazi T, Almutairi AZ, Alosaimi B, Mubarak A, Choudhary RK, Alturaiki W. Clinical characteristics and predictors of mortality among COVID-19 patients in Saudi Arabia. J Infect Public Health. 2021 Aug;14(8):994-1000.
[17] Chinnadurai, R., Ogedengbe, O., Agarwal, P. et al. Older age and frailty are the chief predictors of mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting- a cohort study. BMC Geriatr 2020; 20, 409-14.
[18] Rastad H, Karim H, Ejtahed HS, Tajbakhsh R, Noorisepehr M, Babaei M, et al. Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease. Diabetol Metab Syndr. 2020 Jul 6;12:57.
[19] Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Sarriá Cabrera MA, Maffei de Andrade S, Sequí-Dominguez I, Martínez-Vizcaíno V. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and metaanalysis exploring differences by age, sex and health conditions. PLoS One. 2020 Nov 3;15(11):e0241742.
[20] Chinnadurai, R., Ogedengbe, O., Agarwal, P. et al. Older age and frailty are the chief predictors of mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting- a cohort study. BMC Geriatr 2020; 20, 409.
[21] Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-NET, 14 states, March 1-30, 2020. Centers for Disease Control and Prevention: MMWR. 2020;69(15):458-464.
[22] CDC. Coronavirus (COVID-19): symptoms of coronavirus. Centers for Disease Control and Prevention. 2020.
[23] Aksel G, İslam MM, Algın A, Eroğlu SE, Yaşar GB, Ademoğlu E, Dölek ÜC. Early predictors of mortality for moderate to severely ill patients with Covid-19. Am J Emerg Med. 2021 Jul; 45:290-296.
[24] Shi C, Wang C, Wang H, Yang C, Cai F, Zeng F, et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study. Clin Transl Sci. 2020; 13:1087-95.
[25] Mehraeen E, Karimi A, Barzegary A, Vahedi F, Afsahi AM, Dadras O, Moradmand-Badie B, Seyed Alinaghi SA, Jahanfar S. Predictors of mortality in patients with COVID-19-a systematic review. Eur J Integr Med. 2020 Dec; 40:101226.
[26] Gómez-Pastora J, Weigand M, Kim J, Wu X, Strayer J, Palmer AF, Zborowski M, Yazer M, Chalmers JJ. Hyperferritinemia in critically ill COVID-19 patients - Is ferritin the product of inflammation or a pathogenic mediator? Clin Chim Acta. 2020 Oct; 509:249-251.
[27] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 2020; 395: 497-506.